Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression

Venetoclax is highly active in some patients with myeloma, but beyond the t(11;14) subset this has not been well defined. Gupta et al demonstrate that venetoclax-sensitive myeloma retains a B-cell-like pattern of gene expression and chromatin accessibility. They provide preliminary evidence that this expression pattern is a better biomarker for predicting venetoclax response than t(11;14) alone.

• Publication year

  2021

• Venue

  Blood

• Publication date

  2021-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood.2020007899PMID 33649772PMCID 8462405
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma

  2019cited by this paper
• B cell activation and plasma cell differentiation are inhibited by de novo DNA methylation

  2018cited by this paper
• Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities

  2018cited by this paper
• Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

  2018cited by this paper
• Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma.

  2018cited by this paper
• BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment.

  2018cited by this paper
• AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.

  2018cited by this paper
• Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma

  2017cited by this paper
• BH3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma

  2017cited by this paper
• Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.

  2017cited by this paper
• Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.

  2017cited by this paper
• How is patient care for multiple myeloma advancing?

  2017cited by this paper
• Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.

  2017cited by this paper
• The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

  2016cited by this paper
• Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1.

  2016cited by this paper
• Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

  2016cited by this paper
• Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

  2016cited by this paper
• Plasma cell differentiation is coupled to division-dependent DNA hypomethylation and gene regulation

  2016cited by this paper
• ATAC-seq on biobanked specimens defines a unique chromatin accessibility structure in naïve SLE B cells

  2016cited by this paper
• Transcriptional profiling of mouse B cell terminal differentiation defines a signature for antibody-secreting plasma cells

  2015cited by this paper
• Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax

  2015cited by this paper
• BH3-profiling identifies heterogeneous dependency on Bcl-2 family members in Multiple Myeloma and predicts sensitivity to BH3 mimetics

  2015cited by this paper
• Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma.

  2014cited by this paper
• The Tao of myeloma.

  2014cited by this paper
• Plenary Papers (356 articles)

  2013cited by this paper
• Mcl-1 is essential for the survival of plasma cells

  2013cited by this paper
• ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

  2013cited by this paper
• Reprogramming cell death: BCL2 family inhibition in hematological malignancies.

  2013cited by this paper
• The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

  2013cited by this paper
• Specificity through cooperation: BATF–IRF interactions control immune-regulatory networks

  2013cited by this paper
• Genetic Screens in Human Cells Using the CRISPR-Cas9 System

  2013cited by this paper
• ABT-737 is highly effective against molecular subgroups of multiple myeloma.

  2011cited by this paper
• Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells.

  2011cited by this paper
• Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases

  2011cited by this paper
• Multiple myeloma.

  2011cited by this paper
• The BCL-2 family reunion.

  2010cited by this paper
• BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs

  2010cited by this paper
• Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma.

  2008cited by this paper
• BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma.

  2008cited by this paper
• From bloodjournal.hematologylibrary.org at PENN STATE UNIVERSITY on February 21, 2013. For personal use only.

  2007cited by this paper
• Bcl‐2 changes conformation to inhibit Bax oligomerization

  2006cited by this paper
• Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation.

  2003cited by this paper
• Myeloid cell factor-1 is a critical survival factor for multiple myeloma.

  2002cited by this paper
• Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells.

  2001cited by this paper

• Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.

  2026cites this paper
• Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study.

  2025cites this paper
• Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells.

  2025cites this paper
• Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple Myeloma

  2025cites this paper
• Myeloma mesenchymal stem cells’ bioenergetics afford a novel selective therapeutic target

  2025cites this paper
• Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax

  2025cites this paper
• A rare case of multiple myeloma with double translocations: t(11;14) and t(14;16)

  2025cites this paper
• The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy

  2025cites this paper
• BCL2 inhibition for multiple myeloma and AL amyloidosis

  2025cites this paper
• Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention

  2025cites this paper
• Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials.

  2025cites this paper
• Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study

  2025cites this paper
• Efficacy of venetoclax in the treatment of relapsed/refractory light-chain amyloidosis

  2025cites this paper
• European Myeloma Network Group Consensus Statement on the use of next‐generation sequencing for prognostic stratification of newly diagnosed multiple myeloma

  2025cites this paper
• Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML

  2025cites this paper
• Inhibition of FOXM1 Synergizes with BH3 Mimetics Venetoclax and Sonrotoclax in Killing Multiple Myeloma Cells through Repressing MYC Pathway

  2025cites this paper
• Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies

  2024cites this paper
• The Genetic and Molecular Drivers of Multiple Myeloma: Current Insights, Clinical Implications, and the Path Forward

  2024cites this paper
• Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis.

  2024cites this paper
• Expression profile of Bcl‐2 family proteins in newly diagnosed multiple myeloma patients

  2024cites this paper
• Clinical Pharmacology and Side Effects of Venetoclax in Hematologic Malignancies.

  2024cites this paper
• Predictors of response to venetoclax and therapeutic potential of CDK7 inhibition in multiple myeloma

  2024cites this paper
• Inhibition of FOXM1 synergizes with BCL2 inhibitor Venetoclax in killing non-t(11;14) multiple myeloma cells via repressing MYC pathway

  2024cites this paper
• Venetoclax in myeloma: to B, or not to B.

  2024cites this paper
• A neutrophil extracellular trap-related risk score predicts prognosis and characterizes the tumor microenvironment in multiple myeloma

  2024cites this paper
• Cereblon-Targeting Ligase Degraders in Myeloma: Mechanisms of Action and Resistance.

  2024cites this paper
• Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible

  2024cites this paper
• Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells

  2024cites this paper
• Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status

  2024cites this paper
• The epigenetic spectrum of IgM gammopathies.

  2024cites this paper
• Flow cytometric expression of Bcl-2, Mcl-1, and their ratios correlates with primary and secondary cytogenetic changes and their combinations in multiple myeloma

  2024cites this paper
• Precision medicine for multiple myeloma: The case for translocation (11;14).

  2024cites this paper
• The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities

  2024cites this paper
• Bcl-2 inhibition in the treatment of hematologic malignancies

  2023cites this paper
• Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis

  2023cites this paper
• Signaling pathways in cancer metabolism: mechanisms and therapeutic targets

  2023cites this paper
• Aquaporin 3 inhibition suppresses the mitochondrial respiration rate and viability of multiple myeloma cells.

  2023cites this paper
• New Biological Therapies for Multiple Myeloma.

  2023cites this paper
• Integrated Epigenetic and Transcriptional Single-Cell Analysis of t(11;14) Multiple Myeloma and Its BCL2 Dependency.

  2023cites this paper
• Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma

  2023cites this paper
• Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)

  2023cites this paper
• Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review

  2023cites this paper
• RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma

  2023cites this paper
• The Role of t(11;14) in Tailoring Treatment Decisions in Multiple Myeloma

  2023influential citation
• Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects

  2023influential citation
• Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)

  2022cites this paper
• Distinct B-Cell Specific Transcriptional Contexts of the BCL2 Oncogene Impact Pre-Malignant Development in Mouse Models

  2022cites this paper
• Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance

  2022cites this paper
• Magnetic Nanodroplets for Enhanced Deep Penetration of Solid Tumors and Simultaneous Magnetothermal‐Sensitized Immunotherapy against Tumor Proliferation and Metastasis

  2022cites this paper
• Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy

  2022cites this paper
• A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors

  2022influential citation
• Multiple myeloma with t(11;14): unique biology and evolving landscape.

  2022cites this paper
• Venetoclax ex vivo functional profiling predicts improved progression-free survival

  2022influential citation
• Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation

  2022influential citation
• No needles needed: All-oral therapy options for relapsed and refractory multiple myeloma.

  2022cites this paper
• Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges

  2022cites this paper
• Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination

  2022cites this paper
• An update on novel multiple myeloma targets

  2022cites this paper
• Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup

  2022cites this paper
• How do we manage t(11;14) plasma cell disorders with venetoclax?

  2022cites this paper
• PDZ proteins SCRIB and DLG1 regulate myeloma cell surface CD86 expression, growth, and survival.

  2022cites this paper
• Bone Marrow Stroma-Induced Transcriptome and Regulome Signatures of Multiple Myeloma

  2022cites this paper
• Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways

  2022cites this paper
• A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax

  2022cites this paper
• Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma

  2021cites this paper
• Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond

  2021cites this paper
• Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment

  2021cites this paper
• Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity

  2021cites this paper
• Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma

  2021cites this paper
• Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology—Highlights of the 8th Heidelberg Myeloma Workshop

  2021cites this paper
• Multiple myeloma with t(11;14)‐associated immature phenotype has lower CD38 expression and higher BCL2 dependence

  2021cites this paper
• Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14)

  2021cites this paper